JP2015514093A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514093A5
JP2015514093A5 JP2015503582A JP2015503582A JP2015514093A5 JP 2015514093 A5 JP2015514093 A5 JP 2015514093A5 JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015503582 A JP2015503582 A JP 2015503582A JP 2015514093 A5 JP2015514093 A5 JP 2015514093A5
Authority
JP
Japan
Prior art keywords
use according
administered
thymosin alpha
sepsis
alpha peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015503582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514093A (ja
Filing date
Publication date
Priority claimed from US13/835,107 external-priority patent/US20130296223A1/en
Application filed filed Critical
Publication of JP2015514093A publication Critical patent/JP2015514093A/ja
Publication of JP2015514093A5 publication Critical patent/JP2015514093A5/ja
Pending legal-status Critical Current

Links

JP2015503582A 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用 Pending JP2015514093A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017108931A Division JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用

Publications (2)

Publication Number Publication Date
JP2015514093A JP2015514093A (ja) 2015-05-18
JP2015514093A5 true JP2015514093A5 (enExample) 2015-12-17

Family

ID=49261395

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2015503582A Pending JP2015514093A (ja) 2012-03-30 2013-03-28 敗血症の処置のためのチモシンαの使用
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017108931A Pending JP2017214377A (ja) 2012-03-30 2017-06-01 敗血症の処置のためのチモシンαの使用
JP2019120721A Pending JP2019156854A (ja) 2012-03-30 2019-06-28 敗血症の処置のためのチモシンαの使用
JP2021065044A Pending JP2021100983A (ja) 2012-03-30 2021-04-07 敗血症の処置のためのチモシンαの使用
JP2022161403A Pending JP2022176345A (ja) 2012-03-30 2022-10-06 敗血症の処置のためのチモシンαの使用
JP2025076491A Pending JP2025107346A (ja) 2012-03-30 2025-05-02 敗血症の処置のためのチモシンαの使用

Country Status (8)

Country Link
US (5) US20130296223A1 (enExample)
EP (2) EP2841088B1 (enExample)
JP (6) JP2015514093A (enExample)
KR (1) KR20150048663A (enExample)
CN (2) CN107519483A (enExample)
CA (1) CA2866435A1 (enExample)
HK (1) HK1246694A1 (enExample)
WO (1) WO2013149030A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524943A (ja) * 2014-08-12 2017-08-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｓ．アウレウス疾患の予測
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
SMT202400412T1 (it) * 2018-04-20 2024-11-15 Combioxin Sa Trattamento dell'ipotensione con sepsi o shock settico
WO2023285349A1 (en) 2021-07-12 2023-01-19 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
TW252045B (enExample) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
US9205050B2 (en) * 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
MX2009009657A (es) * 2007-03-21 2009-09-22 Bausch & Lomb Fluoroquinolonas para el tratamiento, reduccion, mejora, o prevencion de las infecciones provocadas por las bacterias resistentes a los farmacos antibacterianos.
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
EP2416800A1 (en) * 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽

Similar Documents

Publication Publication Date Title
Eljaaly et al. Plazomicin: a novel aminoglycoside for the treatment of resistant Gram-negative bacterial infections
JP2016074740A5 (enExample)
Kumar An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy
Stryjewski et al. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus
JP2015514093A5 (enExample)
Melton‐Celsa et al. New therapeutic developments against Shiga toxin‐producing Escherichia coli
JP2015529225A5 (enExample)
JP2015518818A5 (enExample)
JP2017526627A5 (enExample)
JP2007514749A5 (enExample)
RU2015132369A (ru) Комбинированная терапия для лечения нозокомиальной пневмонии
JP2010222367A5 (enExample)
JP2016507547A5 (enExample)
FI3616695T3 (fi) Menetelmät keuhkojen sisäisten infektioiden hoitamiseksi
JP2013509389A5 (enExample)
JP2019511496A5 (enExample)
Dinc et al. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis
Yamaoka The bactericidal effects of anti-MRSA agents with rifampicin and sulfamethoxazole-trimethoprim against intracellular phagocytized MRSA
RU2018125622A (ru) Способ применения карримицина против резистетности инфекции, спровоцированной микобактерией туберкулеза
JP2012525391A5 (enExample)
Segarra-Newnham et al. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia
CN107714678B (zh) 紫檀芪在制备mcr-1酶抑制剂中的应用
Terrero Salcedo et al. Oritavancin for the Treatment of Infective Endocarditis due to Gram-positive Organism
JP2010538054A5 (enExample)
Jafari Saraf et al. Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections